Together, these data are internally consistent in positioning METTL3 as a stromal lever of cancer metabolism and progression, while also revealing mechanistic diversity in the immediate tumor-cell targets (RAC3 vs. SLC7A5 vs. ACSL3) and in the mode of delivery (paracrine induction vs. exosomal transfer) (112, 113). The gene discussed is ACSL3; the disease is cancer.